Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apellis Pharmaceuticals
Pharma
Study says top launches were for drugs for untreated diseases
Drugs for untreated diseases and those launched by experienced companies have the best chance to achieve quick uptake, according to a Trinity report.
Kevin Dunleavy
Nov 6, 2024 9:55am
Apellis' weak quarter could signal Syfovre 'nadir': analysts
Nov 5, 2024 3:41pm
Astellas pulls application for Izervay after talks with CHMP
Oct 28, 2024 11:07am
Novartis, Apellis roll out rival datasets in rare kidney disease
Oct 28, 2024 10:03am
Apellis hit with yet another eye drug snub in Europe
Sep 20, 2024 10:06am
Watch out, Novartis. Apellis scores major win in kidney diseases
Aug 8, 2024 2:28pm
